These classes of therapy target specific molecules, such as EGFR, VEGF, PD1, HER2, mTOR, etc. Their use in combination with traditional chemotherapeutic drugs has allowed to achieve significant progress in the treatment of advanced and/or metastatic cancers. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.